The global Viral Vector Production (Research-use) market size is expected to be worth around US$ 5.9 billion by 2030 and it is anticipated to grow at a CAGR of 20.8% during forecast period 2021 to 2030.
The global Viral Vector Production (Research-use) market size is expected to be worth around US$ 5.9 billion by 2030 and it is anticipated to grow at a CAGR of 20.8% during forecast period 2021 to 2030.
Growth Factors
The expanding research base for advanced therapies has primarily driven the market for research applications including preclinical, clinical, and investigational studies.
The outbreak of the COVID-19 pandemic has created lucrative opportunities for the market players, particularly in the vaccine manufacturing sector. The application of viral vectors in vaccine development against SARS-CoV-2 has witnessed remarkable growth in the fiscal year 2020. By far, the manufacturing of viral vectors for research use is impeded by a lack of production capacity to fulfill the growing market needs.
Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/38283
Thus, operating key stakeholders are engaged in implementing new approaches to overcome these challenges and expand production capacities. The improving ratio of clinical success to the number of clinical trials of gene and cell therapy products is a testament to the enhancing manufacturing capabilities.
Report Coverage
| Report Scope | Details |
| Market Size | USD 5.9 billion by 2030 |
| Growth Rate | CAGR of 20.8% From 2021 to 2030 |
| Base Year | 2020 |
| Historic Data | 2017 to 2020 |
| Forecast Period | 2021 to 2030 |
| Segments Covered | Vector Type, Application, Workflow, End-use |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Companies Mentioned | Merck KGaA, Lonza, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Cobra Biologics Ltd., Thermo Fisher Scientific, WaismanBiomanufacturing, Genezen |
Report Highlights
The AAV segment dominated the market for viral vector production (research-use) and accounted for the largest revenue share of 25.0%. The adenovirus segment accounted for a significant revenue share in 2020 owing to the increased employment in covid-19 research. Research institutes such as the University of Oxford, CanSino Biologics, and Johnson and Johnson are engaged in adenoviral vector-based vaccine R&D for SARS-CoV-2. Similarly, the German Center for Infection Research has used attenuated measles vaccine strain for the development of the COVID-19 vaccine.
Lentiviral vectors have witnessed huge success in reprogramming induced Pluripotent Stem Cells (iPSC). This has created opportunities for therapeutic research using iPSC technology. Researchers are also deciphering the potential of Non-integrating lentiviral vectors (NILVs) as a tool to avoid insertional mutagenesis, resulting in the fastest growth of this segment.
The vaccine development segment dominated the market for viral vector production (research-use) and accounted for the largest revenue share of nearly 30.0% in 2020 owing to the tremendous increase in research activity for vaccine development against COVID-19 infection. As a response to the ongoing pandemic, a substantial number of research groups have been working on the development of viral vector-based vaccines.
Viral vectors have been thoroughly studied in various animal models and several viruses have been explored as vaccine vectors eventually entering clinical development. Adenovirus and vaccinia virus are some of the most commonly used viral vectors for vaccine development, owing to their high potential for inducing a strong immune response against a foreign body.
The downstream processing segment dominated the market for viral vector production (research-use) and accounted for the largest revenue share of 55.3% in 2020. Given the growing need for vectors in gene and cell therapy production, the processing and supply of viral vectors are of utmost importance in the research setting, to maintain product quality and yield. This has led to the need for optimizing downstream and upstream processing. The companies are evaluating advanced platforms to overcome the bottleneck in manufacturing.
The downstream processing segment held a significant share in 2020 owing to the highly complex procedures administered to generate polished and purified clinical-grade final products. Also, the high cost associated with purification techniques has led to the high revenue generation in this segment.
The research institutes segment dominated the market for viral vector production (research-use) and accounted for the largest revenue share of 60.0% in 2020. This can be attributed to the high involvement of the global research community in the development of advanced therapies for the treatment of several genetic and acquired diseases that previously lacked an effective treatment paradigm.
The outbreak of the COVID-19 infection has encouraged the research community to shift their focus on the development of a vaccine against the disease in urgency. This increased the demand for viral vectors by the research institutes. Apart from COVID-19, the researchers are engaged in R&D in vaccinology for diseases such as HIV and Hepatitis B, thus leading to significant revenue growth.
North America dominated the viral vector production (research-use) market and accounted for the largest revenue share of 50.0% in 2020. The rapidly growing number of advanced therapy products entering clinical trials, coupled with the presence of key operating players in the region, is the major driving factor for the dominance of the region. the number of cell and gene therapies in the pipeline (phase III trials) reached 362 in the U.S, according to PhRMA. The number is expected to increase twofold if the preclinical pipeline is considered. This growing number depicts the increasing research activity in this space.
Key Players
- Merck KGaA
- Lonza
- FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
- Cobra Biologics Ltd.
- Thermo Fisher Scientific
- WaismanBiomanufacturing
- Genezen
- YPOSKESI
- Advanced BioScience Laboratories, Inc. (ABL, Inc.)
- Novasep Holding S.A.S
- Orgenesis Biotech Israel Ltd (formerly ATVIO Biotech ltd.)
- Vigene Biosciences, Inc.
- General Electric Company (GE Healthcare)
- CEVEC Pharmaceuticals GmbH
- Batavia Biosciences B.V.
- Biovion oy
- Wuxi AppTec Co., Ltd.
- VGXI, Inc.
- Catalent Inc.
- MiltenyiBiotec GmbH
- SIRION Biotech GmbH
- Virovek Incorporation
- BioNTech IMFS GmbH
- VIVEbiotech S.L.
- Creative Biogene
- Vibalogics GmbH
- Takara Bio.
- Cell and Gene Therapy Catapult
- BlueBird Bio
- Addgene, Inc.
- Aldevron, L.L.C.
- Audentes Therapeutics
- BioMarin Pharmaceutical
- RegenxBio, Inc
Market Segmentation
- Vector Type Outlook
- Adeno-associated virus (AAV)
- Lentivirus
- Adenovirus
- Retrovirus
- Others
- Application Outlook
- Cell & Gene Therapy Development
- Vaccine Development
- Biopharmaceutical and Pharmaceutical Discovery
- Biomedical Research
- Workflow Outlook
- Upstream Processing
- Vector Amplification & Expansion
- Vector Recovery & Harvesting
- Downstream Processing
- Purification
- Fill Finish
- Upstream Processing
- End-use Outlook
- Pharmaceutical and Biopharmaceutical Companies
- Research Institutes
- Regional Outlook
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa (MEA)
Click Here to View Full Report Table of Contents
Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/38283
You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333